Article

Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.

Second Department of Internal Medicine, Mie University School of Medicine, Tsu.
Internal Medicine (impact factor: 0.94). 03/1994; 33(2):100-2.
Source: PubMed

ABSTRACT Octreotide acetate, a long-acting somatostatin analogue, is effective in controlling and markedly reducing the symptoms of carcinoid crisis. We report a patient with carcinoid syndrome with prolonged survival for 4.5 years with high dose octreotide therapy and survived for 7.5 years after the first flushing, in spite of episodes of severe carcinoid crisis. Dose escalation was required in order to control carcinoid symptoms, and the final dosage was 5,950 micrograms/day. Although administration of such a high dosage of octreotide has never been reported before, we found that octreotide could be used at this dosage safely without inducing serious side effects, and probably prolonged the patient's survival. Our experience with this case indicates that octreotide acetate is an effective drug in controlling carcinoid crisis and prolonging survival without serious side effects.

0 0
 · 
0 Bookmarks
 · 
19 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

carcinoid crisis
 
carcinoid syndrome
 
control carcinoid symptoms
 
Dose escalation
 
dose octreotide therapy
 
effective drug
 
final dosage
 
first flushing
 
inducing serious side effects
 
long-acting somatostatin analogue
 
octreotide
 
Octreotide acetate
 
patient's survival
 
prolonging survival
 
serious side effects
 
severe carcinoid crisis
 
symptoms
 

H Deguchi